medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2007, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2007; 54 (3)

Evaluation of prothrombin time and partial thromboplastin time on whole blood

Ruiz-Bedolla E, López MB, Dionisio-Abraján I

Language: Spanish
References: 13
Page: 136-143
PDF size: 115.58 Kb.


ABSTRACT

In this paper we present the evaluation of PT and PTT in whole blood using CDP as anticoagulant. We analyzed 196 blood samples to determinate PT and PTT in whole blood and plasma. The values obtained for PT in plasma were 12 to 14 seconds with a media of 12.4 seconds and SD ± 1.4. The values of PT for whole blood were 14 to 17 seconds with a media of 15.3 seconds and SD ± 1.3. The PTT for normal plasma is 20 to 40 seconds with media of 35.1 seconds and SD ± 11.0; the values for whole blood were 22 to 40 seconds with media of 34.9 seconds and SD ± 10. We therefore have think that for these determinations plasma or whole blood may be used; with the advantage that when whole blood is used the amount needed is just 0.5 mL.


REFERENCES

  1. Ruiz BE, Dionisio AI. Valoración del citrato dextrosa fosfato como anticoagulante para efectuar la biometría hemática. Rev Mex Patol Clín 1996; 42: 119-121.

  2. Branum E, Cummins L, Bartilson M et al. Effect of two anticoagulants on leukocyte yield and function and on lysosomal enzyme activity. Clin Chem 1988; 34: 110-113.

  3. Heinrich JJ. Pruebas de coagulación sanguínea. En: Sonnenwirth AC, Jarett L. Métodos y diagnósticos del laboratorio clínico. 8a ed. México: Editorial Médica Panamericana, 1983: 927-952.

  4. Ruiz BE. Determinación del tiempo de protrombina y tiempo de tromboplastina parcial utilizando citrato dextrosa fosfato como anticoagulante. Rev Mex Patol Clín 1996; 44: 158-161.

  5. Torrella GA, Toledo GR, Hondares CM, Calañas SL. Evaluación del anticoagulante citrato dextrosa fosfato para la determinación de parámetros hematológicos en pacientes oncológicos. Rev Mex Patol Clín 2003; 50(2): 77-81.

  6. Sachman AL, Grimer PF. Diagnostic uses of the actived partial thromboplastin time and prothrombin time. Ann Intern Med 1986; 104: 810-816.

  7. Kaplan EB, Sheiner LB, Boeckman AJ et al. The usefulness of preoperative laboratory screening. JAMA 1985; 253: 3576-3578.

  8. Lewis SM. Standardization in haematology. Lab Medica 1988; 5: 25-29.

  9. Kitchens CS. Prolonged activated partial thromboplastin time of unknown etiology: a prospective study of 100 consecutive cases referred for consultation. Am J Hematol 1988; 27: 38-45.

  10. Koepke JA. Partial thromboplastin time test proposed performance guidelines. (ICSH panel on the PTT). Tromb Haemost 1986; 55: 143-144.

  11. Sachman AL, Mushlin AI. Howell does the activated partial thromboplastin time predict postoperative hemorrhage? JAMA 1986; 256: 750-753.

  12. Loeliger EA, Poller L, Samama M et al. Questions and answers on prothrombin time standardization in oral anticoagulant control. Thromb Haemost 1985; 54: 515-517.

  13. Loeliger eA, Besselaar AM, Lewis SM. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost 1985; 53: 148-154.




2020     |     www.medigraphic.com